Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Identification of patients at high risk of secondary extramedullary multiple myeloma development

M. Stork, S. Sevcikova, J. Minarik, P. Krhovska, J. Radocha, L. Pospisilova, L. Brozova, J. Jarkovsky, I. Spicka, J. Straub, P. Pavlicek, A. Jungova, T. Jelinek, V. Sandecka, V. Maisnar, R. Hajek, L. Pour

. 2022 ; 196 (4) : 954-962. [pub] 20211102

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011104

Multiple myeloma (MM) is characterized by malignant plasma cell infiltration of the bone marrow. In extramedullary multiple myeloma (EMD), a subclone of these cells migrates out of the bone marrow. Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic, we analyzed 234 secondary EMD patients to clarify risk factors of secondary EMD development. We found younger age [<65 years; odds ratio (OR) 4·38, 95% confidence interval (CI): 2·46-7·80, P < 0·0001], high lactate dehydrogenase (LDH) levels (>5 μkat/l; OR 2·07, 95% CI: 1·51-2·84, P < 0·0001), extensive osteolytic activity (OR 2·21, 95% CI: 1·54-3·15, P < 0·001), and immunoglobulin A (IgA; OR 1·53, 95% CI: 1·11-2·11, P = 0·009) or the non-secretory type of MM (OR 2·83; 95% CI: 1·32-6·04, P = 0·007) at the time of MM diagnosis to be the main risk factors for secondary EMD development. Newly diagnosed MM (NDMM) patients with subsequent EMD had inferior median progression-free (PFS) and overall (OS) survival when compared to NDMM patients without future EMD [mPFS: 13·8 months (95% CI: 11·4-16·3) vs 18·8 months (95% CI: 17·7-19·9), P = 0·006; mOS: 26·7 months (95% CI: 18·1-35·4) vs 58·7 months (95% CI: 54·8-62·6), P < 0·001]. We found that NDMM patients with specific risk factors associated with secondary EMD development have a more aggressive disease course before secondary EMD develops.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011104
003      
CZ-PrNML
005      
20220506130504.0
007      
ta
008      
220425s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.17925 $2 doi
035    __
$a (PubMed)34726261
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Stork, Martin $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
245    10
$a Identification of patients at high risk of secondary extramedullary multiple myeloma development / $c M. Stork, S. Sevcikova, J. Minarik, P. Krhovska, J. Radocha, L. Pospisilova, L. Brozova, J. Jarkovsky, I. Spicka, J. Straub, P. Pavlicek, A. Jungova, T. Jelinek, V. Sandecka, V. Maisnar, R. Hajek, L. Pour
520    9_
$a Multiple myeloma (MM) is characterized by malignant plasma cell infiltration of the bone marrow. In extramedullary multiple myeloma (EMD), a subclone of these cells migrates out of the bone marrow. Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic, we analyzed 234 secondary EMD patients to clarify risk factors of secondary EMD development. We found younger ag $a Multiple myeloma MM is characterized by malignant plasma cell infiltration of the bone marrow In extramedullary multiple myeloma EMD a subclone of these cells migrates out of the bone marrow Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic we analyzed 234 secondary EMD patients to clarify risk factors of secondary EMD development We found younger age 5 μkat $a Multiple myeloma (MM) is characterized by malignant plasma cell infiltration of the bone marrow. In extramedullary multiple myeloma (EMD), a subclone of these cells migrates out of the bone marrow. Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic, we analyzed 234 secondary EMD patients to clarify risk factors of secondary EMD development. We found younger age [<65 years; odds ratio (OR) 4·38, 95% confidence interval (CI): 2·46-7·80, P < 0·0001], high lactate dehydrogenase (LDH) levels (>5 μkat/l; OR 2·07, 95% CI: 1·51-2·84, P < 0·0001), extensive osteolytic activity (OR 2·21, 95% CI: 1·54-3·15, P < 0·001), and immunoglobulin A (IgA; OR 1·53, 95% CI: 1·11-2·11, P = 0·009) or the non-secretory type of MM (OR 2·83; 95% CI: 1·32-6·04, P = 0·007) at the time of MM diagnosis to be the main risk factors for secondary EMD development. Newly diagnosed MM (NDMM) patients with subsequent EMD had inferior median progression-free (PFS) and overall (OS) survival when compared to NDMM patients without future EMD [mPFS: 13·8 months (95% CI: 11·4-16·3) vs 18·8 months (95% CI: 17·7-19·9), P = 0·006; mOS: 26·7 months (95% CI: 18·1-35·4) vs 58·7 months (95% CI: 54·8-62·6), P < 0·001]. We found that NDMM patients with specific risk factors associated with secondary EMD development have a more aggressive disease course before secondary EMD develops.
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mnohočetný myelom $x mortalita $x patofyziologie $7 D009101
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rizikové faktory $7 D012307
650    _2
$a analýza přežití $7 D016019
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sevcikova, Sabina $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000271946771
700    1_
$a Minarik, Jiri $u Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Krhovska, Petra $u Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Radocha, Jakub $u 4th Department of Internal Medicine - Hematology, Faculty Hospital and Charles University in Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Pospisilova, Lenka $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Brozova, Lucie $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Jarkovsky, Jiri $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Spicka, Ivan $u 1st Medical Department - Clinical Department of Haematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic
700    1_
$a Straub, Jan $u Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Pavlicek, Petr $u Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Jungova, Alexandra $u Hematology and Oncology Department, Charles University Hospital, Pilsen, Czech Republic
700    1_
$a Jelinek, Tomas $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Sandecka, Viera $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Maisnar, Vladimir $u 4th Department of Internal Medicine - Hematology, Faculty Hospital and Charles University in Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Hajek, Roman $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000169556267 $7 nlk20000083645
700    1_
$a Pour, Ludek $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 196, č. 4 (2022), s. 954-962
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34726261 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130456 $b ABA008
999    __
$a ok $b bmc $g 1788943 $s 1162302
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 196 $c 4 $d 954-962 $e 20211102 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace